Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Tuesday 19th September 2017 from 8.00am to 4.00pm (BST).

During this time our website performance may be temporarily affected. If you have any questions please use the feedback button available under our menu button. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 12, 2016
Previous Article Next Article

A copper–amyloid-β targeted fluorescent chelator as a potential theranostic agent for Alzheimer's disease

Author affiliations

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease and is still incurable. Traditional therapies use diagnostic and therapeutic drugs separately, which is unfavourable for exploring the pathology of AD and optimizing the efficacy of drugs. Theranostic agents that combine diagnosis and targeted therapy could overcome the weakness of current approaches through the complementary action between the two functions. Owing to the intense relevance to AD pathogenesis, metal-associated amyloid-β (Aβ) species have been considered as the primary targets for anti-AD. We herein report a fluorescent chelator (BTTA) as a potential theranostic agent for both attenuating and fluorescence imaging of Cu2+-induced Aβ aggregation in the AD brain. Considerable evidence shows that BTTA is able to specifically target Cu2+-associated Aβ aggregates and capture Cu2+ ions to attenuate the aggregates and their neurotoxicity. Most notably, the disaggregation of Cu2+–Aβ aggregates can be monitored by the fluorescence changes of BTTA from both buffer and brain homogenates of AD mice. Moreover, BTTA can also be used to visually detect the Aβ aggregates via fluorescence imaging of slices of brain tissues from AD mice and is verified to penetrate the blood brain barrier of mice in vivo. These findings suggest that BTTA would provide a promising strategy to develop potential theranostic tools for AD.

Graphical abstract: A copper–amyloid-β targeted fluorescent chelator as a potential theranostic agent for Alzheimer's disease

Back to tab navigation

Supplementary files

Publication details

The article was received on 23 Jul 2016, accepted on 01 Oct 2016 and first published on 07 Oct 2016


Article type: Research Article
DOI: 10.1039/C6QI00268D
Citation: Inorg. Chem. Front., 2016,3, 1572-1581
  •   Request permissions

    A copper–amyloid-β targeted fluorescent chelator as a potential theranostic agent for Alzheimer's disease

    T. Yang, L. Yang, C. Zhang, Y. Wang, X. Ma, K. Wang, J. Luo, C. Yao, X. Wang and X. Wang, Inorg. Chem. Front., 2016, 3, 1572
    DOI: 10.1039/C6QI00268D

Search articles by author

Spotlight

Advertisements